Suppr超能文献

用于增强敏化活性并降低毒性的硝基唑类放射增敏剂的氟修饰:药代动力学特征

Fluorine modification of nitroazole radiosensitizers for the enhancement of sensitizing activity with lowering toxicity: a pharmacokinetic characterization.

作者信息

Kagiya V T, Nishimoto S, Ito T, Wang J, Abe M, Sasai K

机构信息

Department of Hydrocarbon Chemistry, Faculty of Engineering, Kyoto University, Japan.

出版信息

Int J Radiat Oncol Biol Phys. 1992;22(3):601-5. doi: 10.1016/0360-3016(92)90886-m.

Abstract

Pharmacokinetic characterization of various nitroazole radiosensitizers was carried out to clarify the effect of fluorine modification of the side-chain groups on the sensitizing activity and the acute toxicity. The in vivo tumor/plasma partition coefficient (PTP) of sensitizers increased with increase in the octanol/water partition coefficient (Pow) up to approximately 0.3 and was almost unity (maximum) for sensitizers with their Pow values larger than approximately 0.3. This relationship was observed commonly for all types of sensitizers independent of the fluorine modification. The in vivo brain/plasma partition coefficient (PBP) of sensitizers increased with increase in the Pow, attaining a constant value of almost unity at Pow greater than 0.5 for non-fluorine sensitizers or at Pow greater than 1.5 for fluorine-modified sensitizers. The maximum brain-affinity factor ((FB,t)max = (CB,t)max/Ds, where (CB,t)max and Ds are the maximum intrabrain concentration and the administered dose of sensitizer, respectively) was proportional to the maximum tumor-affinity factor ((FT,t)max = (CT,t)max/Ds, where (CT,t)max is the maximum intratumor concentration of sensitizer), depending on the side-chain structure of the sensitizer. A series of non-fluorine and fluorine-modified nitroazole derivatives, including N-(2'-hydroxyethyl)-2,2-difluoro-3-(3''-nitro-1'-triazolyl)propionamide (KU-2285), gave a smaller brain to tumor ratio of approximately 1/7. The toxicity index defined by 1/LD50/7 was parallel to the sensitizing activity measured by 1/DS,1.5 (DS,1.5 is the sensitizer dose to obtain the SER of 1.5 in vivo). The therapeutic risk index defined by Ds,1.5/LD50/7 depended on the side-chain structures of sensitizers. The DB,1-5LD50-/7 values of KU-2285 and ethanidazole (SR-2508) were 1/3 that of misonidazole (MISO). The sensitizers were smaller Ds,1.5/LD50/7 values showed higher sensitizing activities as their tumor affinities increased, without an increase in serious toxicity.

摘要

对各种硝基唑类放射增敏剂进行了药代动力学表征,以阐明侧链基团的氟修饰对增敏活性和急性毒性的影响。增敏剂的体内肿瘤/血浆分配系数(PTP)随辛醇/水分配系数(Pow)的增加而增加,直至约0.3,对于Pow值大于约0.3的增敏剂,该系数几乎为1(最大值)。对于所有类型的增敏剂,无论是否进行氟修饰,均普遍观察到这种关系。增敏剂的体内脑/血浆分配系数(PBP)随Pow的增加而增加,对于非氟增敏剂,当Pow大于0.5时达到几乎为1的恒定值;对于氟修饰增敏剂,当Pow大于1.5时达到该恒定值。最大脑亲和因子((FB,t)max = (CB,t)max/Ds,其中(CB,t)max和Ds分别是增敏剂在脑内的最大浓度和给药剂量)与最大肿瘤亲和因子((FT,t)max = (CT,t)max/Ds,其中(CT,t)max是增敏剂在肿瘤内的最大浓度)成正比,这取决于增敏剂的侧链结构。一系列非氟和氟修饰的硝基唑衍生物,包括N-(2'-羟乙基)-2,2-二氟-3-(3''-硝基-1'-三唑基)丙酰胺(KU-2285),脑肿瘤比约为1/7,相对较小。由1/LD50/7定义的毒性指数与由1/DS,1.5测量的增敏活性平行(DS,1.5是在体内获得1.5的增敏比所需的增敏剂剂量)。由Ds,1.5/LD50/7定义的治疗风险指数取决于增敏剂的侧链结构。KU-2285和乙硝唑(SR-2508)的DB,1-5LD50-/7值是甲硝唑(MISO)的1/3。增敏剂的Ds,1.5/LD50/7值越小,随着其肿瘤亲和力增加,增敏活性越高,且严重毒性无增加。

相似文献

5
Radiosensitization in vitro and in vivo by 3-nitrotriazoles.
Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1063-6. doi: 10.1016/0360-3016(86)90226-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验